Some providers featured on this site may compensate us. This may affect the order and placement of listings but does not influence our editorial ratings or reviews.
Retatrutide for Weight Loss: The Next-Gen Drug, Explained
Retatrutide (“reta”) reached roughly 24% weight loss in trials - the most of any weight loss drug so far. Here’s what it is, how it stacks up against tirzepatide and semaglutide, and an honest answer on whether you can actually get it.
Last updated: Sep 1, 2026
First, the honest part
Retatrutide is not yet FDA-approvedand can’t be legitimately prescribed or purchased for weight loss. It’s in late-stage trials, with a possible approval in the 2026-2027 window. This page explains the science and how it compares - and points you to the approved options you can use today.
Our top 2 picks
Our two recommended GLP-1 providers, shown with the same verified pricing and ratings as our full comparison.
embody offers doctor-prescribed GLP-1 weight loss treatment - compounded semaglutide and tirzepatide injections - through a 100% online process. Getting started takes a roughly 5-minute health qualifier, after which a medical practitioner reviews your chart (embody says usually within 24 hours, often under 5). Pricing is flat and simple: $69/month for semaglutide and $119/month for tirzepatide, with no insurance required, no hidden fees, and no clinic visits. Medication ships in 1-2 days in temperature-controlled, tracked, insured packaging, and embody is LegitScript-certified and works with US-based 503A compounding pharmacies. On Trustpilot, embody averages 3.8 across 8,398 reviews - an honest, mixed-to-positive record whose recent reviews cluster around two themes: responsive, proactive customer service ('from my very first inquiry I've had excellent communication... customer service updated me every step,' writes one tirzepatide patient) and the no-surprises pricing ('Love the fact that there are no surprises as in costly up front cost'). A 3.7 also means a minority of customers had negative experiences - worth reading both ends of the reviews before deciding, as with any provider.
altRx bills itself as "the #1 most affordable GLP-1 program," and its published prices largely back that up: compounded GLP-1 (semaglutide) from $89/month and GLP-1 + GIP (tirzepatide) from $149/month - flat at every dose, so the price doesn't climb as you titrate up - alongside one of the few genuine brand-name shelves in this space (Ozempic $1,149, Zepbound $1,249, Wegovy $1,579 per month). It's a self-pay telehealth service: you complete a short assessment, a licensed provider (physician, PA, or nurse practitioner) reviews it, and if appropriate a prescription goes to a licensed US pharmacy, with free shipping in about 5-7 days. No insurance is required, Buy Now, Pay Later is available, and you can pause or cancel anytime. Two things to know before the details: shipping is slower than the 1-2 day providers (embody, DirectMeds), and Trustpilot does not currently display an aggregate score on altRx's profile - the individual reviews we quote on this page are real, but there's no independent average to lean on the way there is for rivals like Medvi (4.3 across 14,836) or embody (3.8 across 8,398). One of the real 4-star reviews we surface notes a refill 'yet to be fulfilled with zero reason as to why' - worth factoring in alongside the price advantage.
Retatrutide is an investigational once-weekly injection from Eli Lilly. What makes it different is that it’s a triple agonist: it activates three receptors at once - GLP-1 and GIP (like tirzepatide) plus a third, glucagon. That extra target is thought to boost metabolism and fat burning on top of the appetite effects, which is why it has produced the largest weight loss seen in trials so far.
In a Phase 2 study published in 2023, participants on the highest retatrutide dose lost about 24% of their body weight over 48 weeks - ahead of tirzepatide (~20%) and semaglutide (~15%) in their own trials. Larger Phase 3 trials are now underway to confirm the effect and its long-term safety. Early results are promising, but Phase 3 outcomes and FDA review are what determine whether - and when - it reaches patients.
What you can use today
Since retatrutide isn’t available yet, the most effective approved options are tirzepatide (~20% weight loss) and semaglutide (~15%). Both are prescribed online by licensed telehealth providers, often as affordable compounded versions. Compare providers on pricing, medical support, and value.
Retatrutide (sometimes called “reta” or a “triple agonist”) is an investigational once-weekly injection from Eli Lilly. Unlike semaglutide (a GLP-1) or tirzepatide (a dual GLP-1/GIP), retatrutide targets three receptors at once - GLP-1, GIP, and glucagon - which is why it has produced the largest weight loss of any drug in trials so far.
How much weight loss does retatrutide cause?
In a Phase 2 trial, participants on the highest dose lost about 24% of their body weight over 48 weeks - more than tirzepatide (~20%) or semaglutide (~15%) in their trials. These are early results; larger Phase 3 trials are underway to confirm them.
Is retatrutide FDA approved?
No. As of 2026, retatrutide is investigational and has not been approved by the FDA for weight loss or any other use. It is being studied in late-stage (Phase 3) clinical trials.
When will retatrutide be available?
It depends on the outcome of its Phase 3 program and FDA review. Industry expectations point to a potential approval in the 2026-2027 window, but timelines can shift. Until it's approved, it cannot be legitimately prescribed for weight loss.
Retatrutide vs tirzepatide - which is more effective?
In their respective trials, retatrutide produced more weight loss (~24%) than tirzepatide (~20%+). But tirzepatide is FDA-approved and available today, while retatrutide is still investigational. For most people the practical comparison is between the approved options - with retatrutide as a promising future addition.
Can you buy retatrutide now?
No. Because it isn't FDA-approved, retatrutide is not legitimately available to purchase or be prescribed for weight loss. Be cautious of any site claiming to sell “retatrutide” - sourcing an unapproved drug carries real safety and legal risks. Stick to approved medications prescribed by a licensed clinician.
More GLP-1 guides
The rest of our weight-loss medication guides, kept to the same verified-price standard.
Sources: Phase 2 retatrutide trial results (New England Journal of Medicine, 2023) and manufacturer trial program information; published data for tirzepatide (SURMOUNT) and semaglutide (STEP). Trial figures are averages; individual results vary. Brand and drug names are trademarks of their respective manufacturers.
treatmentshub.com is not a medical provider and does not prescribe medications. This page is for educational purposes only and is not medical advice. Retatrutide is investigational and not FDA-approved. Always consult a licensed healthcare provider about approved treatment options.
